Taysha Gene Therapies Inc. (TSHA) News
Filter TSHA News Items
TSHA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TSHA News Highlights
- TSHA's 30 day story count now stands at 9.
- Over the past 10 days, the trend for TSHA's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about TSHA are GENE, RARE and VG.
Latest TSHA News From Around the Web
Below are the latest news stories about Taysha Gene Therapies Inc that investors may wish to consider to help them evaluate TSHA as an investment opportunity.
Two Insider Moonshots Rising on Sudden BuyingBiotech insiders are among the most important investors to pay close attention to. |
The Independent Director of Taysha Gene Therapies, Inc. (NASDAQ:TSHA), Paul Manning, Just Bought 3.4% More SharesThose following along with Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) will no doubt be intrigued by the recent... |
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposiumDALLAS, February 09, 2022--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the |
Taysha Gene Therapies Inc. (TSHA) Recovers 20.85% From Low: Are We There Yet?Taysha Gene Therapies Inc. (NASDAQ:TSHA) concluded the trading at $7.94 on Friday, February 04 with a rise of 2.06% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $7.78 with its price kept floating in the range of $7.80 and $8.9299 on Taysha Gene Therapies Inc. (TSHA) Recovers 20.85% From Low: Are We There Yet? Read More » |
Taysha Reports Efficacy, Safety Data From High Dose Cohort For Neurological Disorder Gene Therapy TrialTaysha Gene Therapies Inc (NASDAQ: TSHA ) has reported clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg and long-term durability data across all therapeutic doses of TSHA-120 in giant axonal neuropathy (GAN). 5-point improvement was observed in the rate of decline in MFM32 score for the high dose cohort compared to natural … Full story available on Benzinga.com |
Taysha posts data from high dose cohort for TSHA-120 in giant axonal neuropathyAnnouncing the data for high dose cohort of TSHA-120 in rare inherited disease, giant axonal neuropathy, Taysha Gene Therapies (TSHA) noted that the experimental therapy led to |
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal NeuropathyDALLAS, January 31, 2022--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported positive clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg, as well as long-term durability data across all therapeutic doses of TSHA-120 in gia |
Taysha Gene Therapies (TSHA) Gets a Buy Rating from JMP SecuritiesIn a report released today, Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price target of $40.00. The company's shares closed last Thursday at $6.98. According to TipRanks.com, Tuerkcan is a 3-star analyst with an average return of 9.1% and a 33.3% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Crispr Therapeutics AG, and Intellia Therapeutics. Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $39.17, implying a 397.7% upside from current levels. |
Taysha Gene Therapies (TSHA) Gets a Buy Rating from NeedhamIn a report released today, Gil Blum from Needham maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price target of $47.00. The company's shares closed last Thursday at $7.05. According to TipRanks.com, Blum 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -41.4% and a 5.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Crispr Therapeutics AG. Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $39.17, implying a 397.7% upside from current levels. |
8 Stocks in Eashwar Krishnan’s Tybourne Capital Management PortfolioIn this article, we will take a look at some of the stocks in Eashwar Krishnan’s Tybourne Capital Management portfolio. You can skip our detailed discussion and go to see 5 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio. Eashwar Krishnan serves as the portfolio manager at Tybourne Capital Management, an investment management firm based […] |